

Contents

Preface — VII

Chapter 1

History of pharmaceuticals — 1

- 1.1 History of pharmaceuticals: their evolution — 1
 - 1.1.1 Beginning — 1
 - 1.1.1.2 GlaxoSmithKline — 2
 - 1.1.1.3 Merck and Merck KGaA — 4
 - 1.1.1.3.1 Merck — 6
 - 1.1.1.4 Pfizer — 7
 - 1.1.1.5 Warner Lambert — 8
 - 1.1.1.6 Parke, Davis — 9
 - 1.1.1.7 Upjohn — 9
 - 1.1.1.8 Bayer AG — 10
 - 1.1.1.9 Eli Lilly — 13
 - 1.1.1.10 Abbott — 14
 - 1.1.1.11 Imperial Chemical Industries (ICI) and AstraZeneca — 15
 - 1.1.1.12 Bristol Myers Squibb — 16
 - 1.1.1.13 E. R. Squibb — 16
 - 1.1.1.14 Novartis, Ciba Geigy, Sandoz — 17
 - 1.1.1.14.1 Ciba — 17
 - 1.1.1.14.2 Geigy — 17
 - 1.1.1.14.3 Sandoz — 18
 - 1.1.1.14.4 Novartis — 19
 - 1.1.1.15 Roche — 19
 - 1.1.1.16 Johnson & Johnson — 20
 - 1.1.1.17 Boots — 20
 - 1.1.1.18 Boehringer Ingelheim — 21
 - 1.1.1.19 Sanofi — 21
 - 1.1.20 Aventis — 21
 - 1.1.21 Novo-Nordisk — 22
 - 1.1.21.1 Novo Industri A/S — 22
 - 1.1.21.2 Nordisk Gentofte A/S — 22
 - 1.1.22 Other companies — 23
 - 1.2 Second half of twentieth century and generic pharma companies — 23
 - 1.3 IG Farben's contribution — 24
 - 1.3.1 Sontochin — 25
 - 1.3.1.1 Preparation of sontochin, resochein, and brachysan — 25
 - 1.3.1.2 Salicylic acid — 29

- 1.3.2.1 Introduction — **29**
- Abbreviations — **35**
- Bibliography — **36**

Chapter 2

Business model: brand versus generics, product demand, process selection, and economics — 41

- 2.1 What is a drug? — **41**
- 2.2 Brand and generic drugs — **41**
 - 2.2.1 Brand drugs — **42**
 - 2.2.2 Brand drug development process — **42**
 - 2.2.2.1 Step 1: discovery and development — **43**
 - 2.2.2.2 Step 2: preclinical research — **43**
 - 2.2.2.3 Step 3: clinical research — **44**
 - 2.2.2.4 Step 4: FDA drug review — **46**
 - 2.2.2.5 Step 5: FDA post-market drug safety monitoring — **47**
 - 2.2.3 Manufacturer inspections — **47**
 - 2.2.4 Generic drugs — **48**
 - 2.2.5 Process selection — **49**
 - 2.2.5.1 Batch process — **50**
 - 2.2.5.2 Continuous process — **51**
 - 2.2.5.3 Batch versus continuous process in pharmaceuticals — **53**
- 2.3 Review of brand and generic drug API production — **54**
- 2.4 Review of formulations — **56**
- 2.5 Manufacturing process technologies and their impact on profitability — **58**
- 2.6 Pharma's business model — **62**
 - Abbreviations — **63**
 - References — **63**

Chapter 3

Physical and chemical properties — 69

- 3.1 Molecular weight — **70**
- 3.2 Physical state — **72**
- 3.3 Liquid — **73**
- 3.4 Solid — **73**
- 3.5 Gas — **74**
- 3.6 Material handling — **74**
 - 3.6.1 Gas as a raw material — **75**
 - 3.6.2 Solids as a raw material — **76**
 - 3.6.2.1 Solid feed for batch processes — **77**
 - 3.6.3 Liquid as a raw material and as a solvent — **78**

3.6.4	Density —	78
3.6.5	Viscosity —	78
3.6.6	Solubility —	79
3.6.7	Specific heat —	79
3.6.8	Azeotrope behavior —	79
3.6.9	Heat of formation/reaction —	80
3.6.10	Flammability —	80
3.7	Exploitation of chemical and physical properties —	80
3.7.1	Exploitation of solvents —	81
3.7.2	Solubility and solubility differences —	81
3.7.3	Density differences (phase separation) —	81
3.7.4	Exotherm/heat of reaction —	83
3.7.5	Melting point —	84
3.8	Toxicity —	84
	Abbreviations —	85
	References —	85

Chapter 4

Pharma chemistry/chemical development — 89

4.1	Examples of organic excipients —	89
4.1.1	Saccharin —	90
4.1.2	Butylated hydroxy toluene —	91
4.2	Chemical synthesis product/processes/development —	91
4.2.1	Mycophenolate mofetil —	96
4.2.2	Nevirapine —	101
4.2.3	Chlorosulfonylation reaction —	108
4.2.4	8-Hydroxyquinoline —	109
4.3	Green process development —	116
4.3.1	Unit processes and unit operations —	117
4.3.2	Mass balance —	119
4.3.3	Solvent selection —	120
4.3.4	Stoichiometry —	120
	Abbreviations —	121
	References —	121

Chapter 5

Manufacturing process development and case studies — 125

5.1	Commercialization of APIs —	126
5.2	Considerations for scale-up —	128
5.2.1	Role of process equipment and mutual interaction of chemicals in pharmaceuticals —	129
5.2.2	Role of process equipment —	130

5.2.3	Stoichiometry, mutual interaction of chemicals, and reaction mechanism — 131
5.3	Dimethyl fumarate — 133
5.4	Hydrochlorothiazide — 138
5.5	Benchmarking of chemistries — 139
5.5.1	USP 7109203 — 140
5.5.2	USP 4464537 — 141
5.6	Metformin hydrochloride — 142
5.7	Omeprazole — 145
5.8	Metoprolol — 147
5.9	Modafinil — 150
5.10	Levothyroxine — 154
5.11	Status of the current manufacturing technologies — 155
5.12	Innovation opportunities for API manufacturing — 156
5.13	Nondestructive creation [118, 119] in API manufacturing — 157
5.14	Modular plants — 159
5.14.1	Process design considerations — 161
5.14.1.1	Solvent use/selection — 161
5.14.1.2	Reaction mechanism and order of addition — 162
5.14.2	Dimethyl fumarate — 163
5.14.3	Metformin hydrochloride — 164
5.14.4	Omeprazole — 165
5.14.5	Metoprolol — 166
5.14.6	Modafinil — 166
5.15	Future of technology innovation in API manufacturing — 167
	Abbreviations — 168
	References — 168

Chapter 6

Active pharmaceutical ingredients (API): innovation, design considerations, and waste reduction — 177

6.1	Why low yield and waste happen — 179
6.2	Sources of pharma's waste — 180
6.3	Can pharma's yields and solvent use be improved to achieve net zero emissions? — 180
6.4	Why has the pharma lagged in manufacturing technology innovation? — 181
6.5	Process steps: laboratory to commercialization — 183
6.5.1	Laboratory development — 183
6.5.2	Scale-up considerations — 184
6.5.3	Equipment options — 185
6.6	API examples — 191

6.6.1	Metoprolol — 192
6.6.1.1	USP 6252113 [47] example — 192
6.6.1.2	US 2009/0247642 A1 [48] example — 193
6.6.1.3	Simplified metoprolol process — 194
6.6.2	Hydrochlorothiazide (HCTZ) — 198
6.6.3	Dimethyl fumarate — 201
6.6.4	Omeprazole — 202
6.6.5	Modafinil — 203
6.7	Pharma's continuous improvement process and why it has lagged — 205
	Abbreviations — 208
	References — 208

Chapter 7

Process documentation and operating strategies — 213

7.1	Operating strategies and process documentation — 213
7.1.1	Operating strategies — 213
7.1.2	Process documentation — 216
7.2	Section 1: process and its description — 218
7.2.1	Omeprazole — 218
7.2.1.1	Batch process — 219
7.2.1.2	Continuous process — 220
7.2.2	Metformin hydrochloride — 221
7.2.2.1	Batch/continuous process — 221
7.3	Section 2: process charge and recovery — 223
7.4	Section 3: raw material specifications/properties — 230
7.4.1	4-(2-Methoxyethyl)phenol — 231
7.4.2	Epichlorohydrin — 231
7.4.3	Sodium hydroxide — 231
7.4.4	Ammonia — 232
7.4.5	Methanol — 232
7.4.6	Maleic anhydride — 232
7.4.7	Thiourea — 233
7.4.8	Toluene — 234
7.4.9	Xylene — 234
7.4.10	Dimethyl amine — 235
7.4.11	Ammonia — 236
7.4.12	Hydrochloric acid — 236
7.5	Section 4: process chemistry and heat balance — 236
7.5.1	Process chemistry — 236
7.5.2	Heat and mass balance — 237
7.6	Section 5: process equipment — 240

7.7	Section 6: process conditions and effect of variables —	250
7.7.1	Liquid/solid feeds —	250
7.7.2	Batch process —	251
7.7.3	Continuous process —	251
7.8	Section 7: suggested operating conditions —	252
7.9	Section 8: laboratory synthesis procedure —	252
7.10	Section 9: analytical methods —	253
7.11	Section 10: thermodynamic and physical properties —	257
7.11.1	Heat of reaction —	257
7.11.2	Physical properties —	257
7.11.2.1	Dimethyl sulfate: $(\text{CH}_3)_2\text{SO}_4$ —	258
7.11.2.2	Sodium hydroxide: NaOH (solid) —	259
7.11.2.3	Sulfuric acid: H_2SO_4 (96%) —	259
7.12	Section 11: final product specifications —	259
7.13	Section 12: cleaning and cGMP practices —	262
7.13.1	Cleaning —	262
7.13.2	cGMP —	263
7.14	Section 13: safety, MSDS (now called SDS), and material handling —	264
7.15	14: US Pharmacopeia standards —	268
	Abbreviations —	272
	References —	272

Chapter 8

Road Map — 277

8.1	Why manufacturing technology innovation has lacked in API manufacturing? —	277
8.2	Why and how the current API manufacturing scenario developed? —	278
8.3	Cost of drugs —	280
8.4	Review of the laboratory process —	283
8.5	Why innovation is needed in pharma? —	287
8.6	Transformational innovation/creative destruction —	289
8.7	Nondestructive creation —	291
8.8	Why excess solvent is used? —	293
8.9	Continuous processing —	293
8.10	Equipment —	297
8.11	Regulations and technology —	298
	Abbreviations —	302
	References —	302